Article
Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
Pharmacogenetics and genomics - 1 Apr 2015
Safgren Stephanie L, Suman Vera J, Kosel Matthew L, Gilbert Judith A, Buhrow Sarah A, Black John L, Northfelt Donald W, Modak Anil S, Rosen David, Ingle James N, Ames Matthew M, Reid Joel M, Goetz Matthew P
Abstract excerpt
BACKGROUND: In tamoxifen-treated patients, breast cancer recurrence differs according to CYP2D6 genotype and endoxifen steady-state concentrations (Endx Css). The ¹³C-dextromethorphan breath test (DM-BT), labeled with ¹³C at the O-CH3 moiety, measures CYP2D6 enzyme activity. We sought to examine the ability of the DM-BT to identify known CYP2D6 genotypic poor metabolizers and examine the correlation between DM-BT...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.